Curis Inc.
45 Moulton Street
Cambridge,
MA 02138
United States - Map
Phone: 617-503-6500
Fax: 617-503-6501
Web Site: http://www.curis.com
| Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor. The company was founded in 2000 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Daniel R. Passeri MSc., J.D., 48
Chief Exec. Officer, Pres |
$
384.00K |
$
0 | Mr. Michael P. Gray , 38
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec. |
$
292.00K |
$
0 | Mr. Mark W. Noel , 50
VP of Technology Management and Intellectual Property |
$
206.00K |
$
19.00K | Dr. Joseph M. Davie Ph.D., 69
Chairman of Scientific Advisory Board, Interim Chief Scientific Officer |
$
21.00K | N/A | Dr. Changgeng Qian Ph.D., M.D., 53
VP of Discovery & Preclinical Devel. |
$
245.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 0.00%
Profile
